Drug Manufacture Progress in MorphoSys’ Phase 3 Myelofibrosis Program.By MohamedMis2July 17, 2023 MorphoSys, the German biotech company, has delivered positive news to its shareholders. The Phase 3 myelofibrosis program is progressing 16%…
Financial Advancing Towards Myelofibrosis BreakthroughBy MohamedMis2July 12, 2023 MorphoSys is on track to complete its Phase 3 myelofibrosis program 16% faster than originally planned. [1] However, there is…
